Key statistics dashboard for Lyell Immunopharma, Inc. (LYEL). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial,...
Stock Data
| Price | $10.78 |
| Market Cap | $264M |
| Enterprise Value | $228.0M |
| Beta | -0.07 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.67 |
| Price / Book | 1.08 |
| P/S | 9779.05 |
| EV/EBITDA | -0.95 |
| EV/Sales | 8443.83 |
| EV/FCF | -1.70 |
| P/FCF | -1.97 |
| Earnings Yield | -98.70% |
| FCF Yield | -50.74% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -8537.04% |
| EBIT Margin | -920285.19% |
| EBITDA Margin | -885037.04% |
| Operating Margin | -711329.63% |
| Net Margin | -920285.19% |
| Return on Equity | -91.62% |
| Return on Assets | -79.86% |
| Return on Invested Capital | -70.80% |
| Return on Capital Employed | -70.80% |
Financial Health
| Current Ratio | 5.36 |
| Quick Ratio | 5.36 |
| Cash Ratio | 1.83 |
| Debt / Equity | 0.16 |
| Debt / Assets | 11.87% |
| Net Debt / EBITDA | 0.15 |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -4.46 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 10.01 |
| Cash per share | 8.74 |
| FCF per share | -5.73 |
| Tangible Book Value per share | 10.01 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 3 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 7 |
| Avg rating (1-5) | 0.29 |
Related companies: ACIU · ALDX · ALLO · AMRN · CABA · EDIT · GNLX
Explore sector: Healthcare · Biotechnology
More sections of LYEL: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks